- Home
- PYPD
PYPD
PolyPid Ltd.
as 07-26-2024 4:00pm EST
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
| Founded: | 2008 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 20.3M | IPO Year: | 2020 |
| Target Price: | $12.00 | AVG Volume (30 days): | 8.1K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 16.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.38 - $12.00 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PolyPid Ltd. News
PYPD Breaking Stock News: Dive into PYPD Ticker-Specific Updates for Smart Investing
MT Newswires
24 days ago
PolyPid Registers $200 Million Ordinary Stock
GlobeNewswire
a month ago
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
GlobeNewswire
2 months ago
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial
Insider Monkey
3 months ago
PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript
GlobeNewswire
3 months ago
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
3 months ago
PolyPid to Participate in Citizens JMP Life Sciences Conference
GlobeNewswire
3 months ago
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
GlobeNewswire
3 months ago
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
Compare PYPD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PYPD PolyPid Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.